SCHEMBL18609282

SCHEMBL18609282

Cc1cccc(F)c1C(=O)N1CCCC(C(=O)Nc2cccc(C(C)(C)C)c2)C1c1ccc(CN2CCCC2C(C)(C)O)cc1

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
UBE2M P61081 3/20 0.36
DCUN1D1 Q96GG9 3/20 0.36
CCR1 P32246 1/20 0.36
MAPK14 Q16539 1/20 0.35
ALDH1A1 P00352 3/20 0.35
USP2 O75604 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
ALK Q9UM73 1/20 0.34
ACKR3 P25106 1/20 0.33
GAA P10253 1/20 0.33
HSD17B10 Q99714 1/20 0.33
GCGR P47871 1/20 0.33
GIPR P48546 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21163658 1.00 UBE2M (0.36) UBE2MDCUN1D1CCR1MAPK14ALDH1A1
SCHEMBL14960538 1.00 UBE2M (0.36) UBE2MDCUN1D1CCR1MAPK14ALDH1A1
SCHEMBL12176635 0.96 UBE2M (0.37) UBE2MDCUN1D1CCR1MAPK14ALDH1A1
SCHEMBL29726764 0.94 DCUN1D1 (0.38) UBE2MDCUN1D1CCR1MAPK14ALDH1A1
SCHEMBL12176427 0.94 DCUN1D1 (0.38) UBE2MDCUN1D1CCR1MAPK14ALDH1A1
SCHEMBL12160879 0.94 DCUN1D1 (0.38) UBE2MDCUN1D1CCR1MAPK14ALDH1A1
SCHEMBL13304257 0.94 DCUN1D1 (0.38) UBE2MDCUN1D1CCR1MAPK14ALDH1A1
SCHEMBL12176458 0.94 DCUN1D1 (0.38) UBE2MDCUN1D1CCR1MAPK14ALDH1A1
SCHEMBL18790163 0.94 DCUN1D1 (0.38) UBE2MDCUN1D1CCR1MAPK14ALDH1A1
SCHEMBL18532689 0.94 DCUN1D1 (0.38) UBE2MDCUN1D1CCR1MAPK14ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230102258-A1 C5AR ANTAGONISTS CHEMOCENTRYX, INC. 2023-03-30 US disclosed
EP-3078658-B1 C5AR ANTAGONISTS CHEMOCENTRYX INC (US) 2019-04-10 EP disclosed
US-20170065604-A1 C5aR ANTAGONISTS CHEMOCENTRYX, INC. 2017-03-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230102258-A1 C5AR ANTAGONISTS C5AR1, C5AR2, C3AR1 UBE2M 4268/4885DCUN1D1 1926/4885CCR1 58/4885
US-20170065604-A1 C5aR ANTAGONISTS C5AR1, C5AR2, C3AR1 UBE2M 4188/4885DCUN1D1 2149/4885CCR1 79/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.